Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in pretreated metastatic NSCLC with MET or ROS1 alterations
NCT02499614Phase 2Unknown
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Dec 2014
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Status: unknown.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02499614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499614.